Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. AAPL
6. RTB
7. ONON
8. AZN
9. SPCX
10. TRMD

Go back to Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population

Alnylam Pharmaceuticals (ALNY) PT Raised to $250 at Morgan Stanley

June 24, 2024 12:28 PM EDT

Morgan Stanley analyst Andrew Galler raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $250.00 (from $164.00) while maintaining a Equalweight rating.

The analyst comments "Top-line HELIOS-B results better-than-expected, supporting sNDA filing in late 2024. We expect focus to now shift to presentation of... More

RBC Capital Positive on Alnylam Pharmaceuticals (ALNY): 'HELIOS-B Hits Convincingly Across the Board, Materially Exceeding Expectations'

June 24, 2024 11:38 AM EDT

RBC Capital analyst Luca Issi reiterated an Outperform rating and $235.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst comments "The News: Highly anticipated HELIOS-B hits the primary endpoint (composite of all-cause mortality and recurrent CV events) in both ITT (HR 0.718, p-value 0.0118; n=654) and monotherapy (HR... More

Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

June 24, 2024 7:28 AM EDT

Stifel analyst Paul Matteis reiterated a Buy rating and $247.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst comments "We believe topline HELIOS-B data are highly positive and support vutrisiran becoming a blockbuster in TTR-cardiomyopathy. Specifically the trial met all... More

Alnylam Pharma (ALNY) to Resume Trading at 7:30 a.m.

June 24, 2024 7:11 AM EDT

Alnylam Pharma (NASDAQ: ALNY) to Resume Trading at 7:30 a.m.

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population Achieved 28% and 33% Reduction in Composite... More